2025-04-03 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Report

**0. Executive Summary:** Intuitive Surgical Inc. (ISRG), a leading medical device company specializing in robotic-assisted surgery, has significantly outperformed the S&P 500 (VOO) over the analyzed period.  While recent performance shows some moderation, the company demonstrates strong profitability and substantial growth potential, though with some increased market risk.

**1. Performance Comparison & Alpha/Beta Analysis:**

ISRG's cumulative return (213.71%) drastically surpasses the S&P 500's (89.44%) return. The current relative divergence of 77.2% indicates ISRG's performance is significantly higher than the S&P 500 compared to its historical range of divergence (165.0% to -13.4%).

The Alpha/Beta analysis reveals varying performance across different periods. While showing substantial CAGR (Compound Annual Growth Rate), the high maximum drawdown (MDD) in some periods indicates significant risk. The Beta consistently exceeds 1, indicating higher volatility than the market.  Positive Alpha values in later years suggest outperformance relative to the market, but this needs to be considered alongside the risk.  The increasing market capitalization (Cap(B)) shows consistent growth.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 66.0% | 10.1% | -0.1 | 44.1 |
| 2016-2018  | 77.0% | 49.6% | -0.1 | 57.9 |
| 2017-2019  | 82.0% | 49.6% | 0.2 | 71.4 |
| 2018-2020  | 53.0% | 49.6% | 0.3 | 98.8 |
| 2019-2021  | 100.0% | 18.4% | 0.3 | 130.2 |
| 2020-2022  | 17.0% | 53.7% | 0.3 | 96.2 |
| 2021-2023  | 19.0% | 55.0% | 0.9 | 122.3 |
| 2022-2024  | 103.0% | 55.0% | 0.9 | 189.2 |
| 2023-2025  | 124.0% | 55.0% | 0.8 | 179.9 |


**2. Recent Price Movement:**

* **Closing Price:** $496.36
* **Last Market Price:** $502.18 (a $1.17 increase from the previous close)  This represents a small, positive daily change.
* **5-Day Moving Average:** $500.08
* **20-Day Moving Average:** $501.88
* **60-Day Moving Average:** $552.56

The price is currently below all three moving averages, suggesting a potential short-term downward trend.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4354 (Medium Risk) –  Suggests a moderate level of risk.
* **RSI:** 49.56 – Close to neutral; neither overbought nor oversold.
* **PPO:** 0.4442 – Positive, suggesting potential upward momentum.
* **20-Day Relative Divergence Change:** -5.8% – Indicates a recent short-term downward trend.
* **Expected Return:** 27.2% –  A significant expected return over the S&P 500 over a long-term (2+ years) investment horizon.  The last market price increase of $1.17 is not significant enough to classify as a sharp upward movement.

**4. Recent Earnings Analysis:**

The earnings data shows relatively consistent revenue growth and EPS (Earnings Per Share), though there's some fluctuation. Further analysis, such as comparing YoY (Year-over-Year) growth and understanding the factors contributing to this growth, is required for a complete picture.

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2024-10-18 | 1.59 | $2.04B        |
| 2024-07-19 | 1.48 | $2.01B        |
| 2024-04-19 | 1.54 | $1.89B        |
| 2023-10-20 | 1.18 | $1.74B        |
| 2024-10-18 | 1.18 | $1.74B        | *(Duplicate entry - Possible data entry error)*


**5. Financial Information:**

Revenue shows consistent growth, and profit margins remain high and relatively stable, indicating strong profitability. ROE (Return on Equity) fluctuates but generally remains positive, showing efficient use of shareholder equity.  The increase in Equity over time signifies company growth.


* **Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |


* **Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |
| 2024-03-31 | $13.96B | 3.90% |
| 2023-12-31 | $13.31B | 4.56% |


**6. Overall Conclusion:**

ISRG exhibits strong long-term growth potential, backed by consistent revenue growth, high profit margins, and substantial market share in robotic surgery.  However, investors should be aware of the inherent volatility associated with the stock, reflected in the high Beta and periods of significant drawdowns.  The moderately high market risk (MRI) and recent short-term price decline indicate a need for caution.  The high expected return, however, makes it an attractive investment for long-term investors with a higher risk tolerance. Further investigation into the drivers of the revenue and earnings growth and a detailed risk assessment are recommended before making any investment decisions.  The duplicate data entry in the earnings table necessitates a verification of the data source.
